{"groups":[{"description":"Docetaxel (TXT) 75 mg/m\\^2 intravenous (IV) infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until disease progression (DP), unacceptable toxicity or participant's refusal.","id":"FG000","title":"Docetaxel 75 mg/m^2"},{"description":"Cabazitaxel 20 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"FG001","title":"Cabazitaxel 20 mg/m^2"},{"description":"Cabazitaxel 25 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"FG002","title":"Cabazitaxel 25 mg/m^2"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"4"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"comment":"Randomized","groupId":"FG000","numSubjects":"391"},{"comment":"Randomized","groupId":"FG001","numSubjects":"389"},{"comment":"Randomized","groupId":"FG002","numSubjects":"388"}],"type":"STARTED"},{"achievements":[{"comment":"For 1 participant, actual treatment received was Cabazitaxel 25 mg/m\\^2.","groupId":"FG000","numSubjects":"388"},{"comment":"For 15 participants, actual treatment received was Cabazitaxel 25 mg/m\\^2.","groupId":"FG001","numSubjects":"382"},{"comment":"For 2 participants, actual treatment received was Cabazitaxel 20 mg/m\\^2.","groupId":"FG002","numSubjects":"377"}],"type":"Treated"},{"achievements":[{"comment":"Completed participants included those who withdrew treatment consent but were followed for survival.","groupId":"FG000","numSubjects":"389"},{"comment":"Completed participants included those who withdrew treatment consent but were followed for survival.","groupId":"FG001","numSubjects":"385"},{"comment":"Completed participants included those who withdrew treatment consent but were followed for survival.","groupId":"FG002","numSubjects":"384"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"4"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 1168 participants randomized in this study. Of these, 21 participants randomized but not treated. These participants were included in intent-to-treat (ITT) population, not in safety population. \"Study cut-off date\" for outcome measures was up to \"primary completion date\" (PCD) only. After PCD, only adverse event (AE) data was updated.","recruitmentDetails":"The study was conducted at 159 centers in 25 countries. A total of 1510 participants were screened between 17 May 2011 and 09 September 2015 of whom 1168 participants were randomized and 342 were considered as screen failures."}